Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 30 October, 2001

Xenova Group PLC


Xenova Group PLC
30 October 2001

For Immediate Release

                               Xenova Group plc

           Board Changes and Appointment of New Commercial Director

Slough, UK, 30th October 2001 - Xenova Group plc (Nasdaq NM: XNVA; London
Stock Exchange: XEN) today announced that Commercial Director Mr Nick Hart
will resign from the Board effective 31 December 2001. He will remain with
Xenova on a part time basis for a short period after 31 December.  Mr Hart
will be joining UK-based Bioscience Managers Limited, a corporate and
investment advisory firm specialising in the life science sector.  He joined
Xenova following the merger with Cantab Pharmaceuticals plc (Cantab) in April
2001.  Mr Hart joined Cantab as Finance Director in 1990 and was acting Chief
Executive of Cantab during the period immediately prior to the Xenova/Cantab

Dr Joy Barton will join Xenova on 5 November 2001 as Commercial Director,
based at Slough, UK and will become a member of the senior management team.
Dr Barton joins Xenova from Accenture, (formerly Andersen Consulting), where
she has specialised in providing consultancy to the pharmaceutical industry on
the commercialisation of key products resulting from research & development.

Dr Stephen Inglis will also resign from the Board effective 31 December 2001
in order to take up an appointment as Director of the National Institute of
Biological Standards and Control (NIBSC).  Dr Inglis joined Xenova as Research
Director, Biologics, following the merger with Cantab in April 2001.  He was
previously Research Director, Cantab.  Before joining Cantab in 1989 as Head
of Molecular Sciences, he was a lecturer in Virology in the Department of
Pathology at Cambridge University.

David Oxlade, Xenova's Chief Executive Officer, commented:

'Nick and Stephen have made a considerable contribution to the successful
merger completed earlier this year, and will be missed.  We wish them every
success in their new roles and thank them both for their significant
contributions to both Cantab and more recently Xenova. I also welcome Joy to
Xenova; her specialist commercial experience in the pharmaceutical field will
be of great value to our team.'



Xenova Group plc                                  Financial Dynamics
Tel: +44 (0) 1753 706600                          Tel: +44 (0) 207 831 3113
David Oxlade: Chief Executive Officer             David Yates/Fiona Noblet
Daniel Abrams: Finance Director
John St Clair Roberts: Medical Director

Hilary Reid Evans: Corporate Communications


BMC  Communications

Tel: 001 212 477 9007

Brad Miles (Ext 17)/Lauren Tortorete (Ext 20)

Notes to Editors

Xenova's product pipeline focuses principally on the therapeutic areas of
cancer, infectious, autoimmune and cardiovascular diseases.  The Group has a
well-established track record in the identification, development and
partnering of innovative products and technologies.  Xenova has partnerships
with a number of major pharmaceutical companies including Lilly, Pfizer,
Celltech and QLT Inc.

For further information about Xenova and its products please visit the Xenova
website at

Safe Harbor Statement under the US Private Securities Litigation Reform Act of
1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995.  Actual results of events could differ materially from those described
in the forward-looking statements due to a variety of factors, including those
set forth in the Company's filings with the US Securities and Exchange